New study aims to sharpen prostate cancer treatment choices with genomic test and MRI
NCT ID NCT04541030
First seen Jan 06, 2026 · Last updated Jun 12, 2026 · Updated 25 times
Summary
This study looks at whether combining a genetic test (called the Genomic Prostate Score, or GPS) with MRI scans can help doctors better choose which men with prostate cancer are good candidates for focal therapy—a treatment that targets only the cancerous part of the prostate. Researchers will review past data and tissue samples from 241 men with low- or intermediate-risk prostate cancer. The goal is to see if the GPS score relates to hidden high-risk disease that MRI might miss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Institute (NCI)
Bethesda, Maryland, 20892, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
Explore the condition pages connected to this study.